Why I like Medmira going forward.Business Development
While the regulatory approvals are in place, MedMira’s local distribution partner in the
South East Asia region is experiencing delays in securing sales contracts for MiraWell
HIV in private and public sectors. MedMira continues to pursue new opportunities
elsewhere in the region to increase our presence in this lucrative market.
The World Health Organization (WHO) continues its evaluation on rapid HIV diagnostics under the new Diagnostics Prequalification Programme launched in June 2008. No recent updates on the process and timeline for results have been released by the WHO.
MedMira’s efforts to develop new revenue streams continues with a focus on high
volume markets, strategic partnerships, and new sales campaigns in existing markets
including the United States and Canada.
With outsourced manufacturing capabilities now fully realized, MedMira is positioned to
meet the demands and price complexities inherent in developing markets including Asia,Africa, and Latin America. The China diagnostics market seems to be rebounding afteran 18-month reorganization at the State Food and Drug Administration and new testing programs are being launched once again. MedMira continues to work with its partner Healthcare Asia and is seeking other local partners with a strong sales, marketing and business development experience in the market.
Building strong relationships with world class companies who share MedMira’s vision will
be critically important in fostering new business opportunities and innovation. Strategic
partnerships are a key component of our plan moving forward and the Company is
currently re-evaluating our existing distribution network to transform these relationships into partnerships that will bring mutual benefit.
MedMira is also assessing the Company’s efforts in the United States and Canada to
see how campaigns and promotional initiatives in these regions can be amplified to
increase sales.
A good NR (big sales or approval by the WHO) is overdue imo